Option chain shows key data for Tofla Megaline's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Tofla Megaline.

Tofla Megaline (OTC:TFLM) Stock, Option Chain

Tofla Megaline Inc is a development stage company engaged in developing the software for security systems in Mexico. The company plan to provide easy-to-use, high quality and cost-effective automation AI solutions. It will be focusing on both stand-alone and integrated solutions to cover a broader selection of services, especially in the surveillance area. Using autonomous robotic units as a means of surveillance is a new tendency all over the globe. Robotic units can be used for patrolling warehouses, malls, backyards, office areas and buildings, etc its focus is going to be developing specialized software for the units that will cover all the necessary functionality for surveillance and data transfer.

TOFLA MEGALINE INC by TOFLA MEGALINE INC.

Tofla Megaline Inc

WIIM

RCEL

Avita Medical shares are trading lower after Lake Street cut its price target on the stock from $20 to $14.

Keybanc analyst Sangita Jain maintains Parsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) with a Overweight and lowers the price target from $122 to $102.

News

Price Target

Analyst Ratings

Keybanc Maintains Overweight on Parsons, Lowers Price Target to $102

Keybanc analyst Scott Schoenhaus maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Overweight and raises the price target from $28 to $30.

Keybanc Maintains Overweight on Phreesia, Raises Price Target to $30

Trading Ideas

XXII

22nd Century Group Shares Resume Trade

While Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang may be regarded as a hero within the broader technology ecosystem, the entrepreneur isn't attracting much love for <a href="https://www.benzinga.com/markets/equities/25/01/42867168/nvidias-jensen-huang-said-something-that-has-all-quantum-computing-stocks-tumbling-qubt-and-rgti-down-13-ionq-down-11">his straight talk</a>. 
With the practicality of innovations such as quantum computing potentially several years away, the blunt assessment triggered a sector-wide selloff, taking down conversational artificial intelligence specialist SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>).
To be fair, Huang — during Nvidia's analyst day — expressed optimism about the future of quantum computing. Nevertheless, the executive mentioned that the innovation struggles with large data due to the underlying microwave-based communication. As such, he projected that practical applications may be 15 to 30 years away.
See Also: <a href="https://www.benzinga.com/news/econ-s/25/01/42884303/fed-minutes-reveal-inflation-jitters-policymakers-signal-slower-interest-rate-easing-path-ahead">Fed Minutes Reveal Inflation Jitters, Policymakers Signal Slower Interest Rate Easing Path Ahead</a>
Subsequently, such a timeline <a href="https://www.benzinga.com/25/01/42860509/soundhound-ai-shares-drop-amid-sector-weakness-whats-going-on">extends a competitive runway</a> for SoundHound's rivals, which may have contributed to the volatility in SOUN stock. While SoundHound isn't directly tied to quantum computers, the general concern is that optimism for emerging technologies may have accelerated too quickly.
On a financial note, there's also the matter of <a href="https://www.benzinga.com/quote/SOUN/earnings">valuation</a>. While SoundHound generally beats analysts' earnings expectations, the company continues to post losses. True, the tech specialist enjoys strong revenue growth. However, with shares priced at around <a href="https://finance.yahoo.com/quote/SOUN/key-statistics/">82 times sales</a>, SoundHound stock commands an ultra-rich premium.
As a prior Options Corner article alluded to, <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42828019/bet-on-near-term-pullback-qbts-stock-bear-put-spread">valuation doesn't matter — until it does</a>.
<h2 class="wp-block-heading">Statistical Trends Urge Against A Directional Bet</h2>
Despite the fallout in SoundHound stock, extreme value hunters may be tempted to buy the dip. Because experts agree that quantum computing and other advanced solutions have a bright future, it makes sense to be greedy during periods of extreme fear. However, the empirical data presents a more nuanced take.
In the past 141 weeks, there have been 34 instances when SoundHound lost 10% of value or more within a one-week period (Monday's open to Friday's close). Out of this bucket, only 18 instances (or 52.94% of the time) resulted in SoundHound delivering a positive return four weeks out.
Currently, trading activity indicates that SoundHound is on pace to post a loss between 20% to 30% for the business week ending Jan. 10. Statistically, 20% or worse weekly losses yield a 46.15% likelihood that the equity will be in positive territory four weeks out. For 30% or worse, the success ratio drops to 40%.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08145805/SOUN-stock-01082025-1024x592.jpg" alt="" class="wp-image-724796" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08145805/SOUN-stock-01082025-1024x592.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08145805/SOUN-stock-01082025-300x174.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08145805/SOUN-stock-01082025-768x444.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08145805/SOUN-stock-01082025.jpg 1032w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Stated differently, there's no indication that traders buy extreme dips in SoundHound stock. Therefore, directional wagers are risky. That said, what is more certain is the magnitude of the response.
Overall, whenever SoundHound suffers a weekly double-digit percentage loss, investors can expect an average positive return of 37.1% and an average loss of 25.8% four weeks out. For losses that specifically land between 20% and 30%, investors may expect an average positive return of 18.55% and an average loss of 24.32%.
<h2 class="wp-block-heading">Charting Out a Long Iron Condor</h2>
With such a wide range of potential pricing outcomes, astute traders may opt for a special multi-leg options strategy called the long iron condor. Structured as a combination of a <a href="https://www.benzinga.com/money/bull-spread">bull call spread</a> and <a href="https://help.benzinga.com/en/articles/6332560-bear-put-spread-options-trade">bear put spread</a>, the transaction speculates that the underlying security will see a rise in implied volatility. In other words, it doesn't matter where SOUN stock goes, so long as it hits either the upside or downside profitability target.
In a long iron condor, the above targets are represented by the outermost strike prices (i.e. the lowest strike price represents the short strike target of the bear put spread and the highest strike price represents the short strike target of the bull call spread).
Based on the empirical data mentioned earlier, traders may reasonably anticipate about a 25% decline in SoundHound stock four weeks from this Friday's close. For the positive scenario, the upside may range between 19% to 37%. 
Assuming a closing price of $15, SoundHound may land between $11.25 and $20.55 by the options chain expiring Feb. 7.
If so, the 12P &#x7C; 13P &#x7C;&#x7C; 17C &#x7C; 18C long iron condor (or the combo of the 12/13 bear put spread and 17/18 bull call spread) would be narrow enough to likely trigger a profitable outcome. However, the maximum payout for this trade presently sits at only 20%.
Assuming a more robust positive response, aggressive traders may consider the 12P &#x7C; 14P &#x7C;&#x7C; 20C &#x7C; 22C long iron condor, which bumps the max payout to 49%. However, wider condors are obviously less likely to trigger their profitability targets, making them increasingly speculative.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/42884764/how-trump-could-impact-chinas-role-in-emerging-greenland-mining-frontier">How Trump Could Impact China&#8217;s Role In Emerging Greenland Mining Frontier</a></li>
</ul>
Image: Shutterstock

Options

Movers

NVDA

SOUN

Options Corner: Trade The Ride, Not The Direction Of SoundHound AI

Keybanc analyst Brett Andress maintains OneWater Marine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEW#NASDAQ">ONEW</a>) with a Overweight and lowers the price target from $27 to $22.

ONEW

Keybanc Maintains Overweight on OneWater Marine, Lowers Price Target to $22

Brown &amp; Brown's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) short percent of float has risen 4.22% since its last report. The company recently reported that it has 4.13 million shares sold short, which is 1.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Brown &amp; Brown Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736369121_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Brown &amp; Brown has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Brown &amp; Brown's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Brown &amp; Brown's peer group average for short interest as a percentage of float is 3.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(BRO) - Analyzing Brown & Brown's Short Interest

TransMedics Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NYSE">TMDX</a>) short percent of float has fallen 7.01% since its last report. The company recently reported that it has 8.64 million shares sold short, which is 31.31% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>TransMedics Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736369116_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TransMedics Gr has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing TransMedics Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, TransMedics Gr's peer group average for short interest as a percentage of float is 8.39%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TMDX

How Is The Market Feeling About TransMedics Gr?

Doximity's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) short percent of float has fallen 5.35% since its last report. The company recently reported that it has 7.03 million shares sold short, which is 5.66% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.69 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Doximity Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736369111_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Doximity has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Doximity's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Doximity's peer group average for short interest as a percentage of float is 5.83%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

DOCS

Looking Into Doximity's Recent Short Interest

Keybanc analyst Scott Schoenhaus maintains ODDITY Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Overweight and raises the price target from $50 to $52.

Keybanc Maintains Overweight on ODDITY Tech, Raises Price Target to $52

Keybanc analyst Sangita Jain maintains MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) with a Overweight and raises the price target from $153 to $168.

Keybanc Maintains Overweight on MasTec, Raises Price Target to $168

22nd Century Group Shares Halted To The Upside; Stock Now Up 45.57%

Keybanc analyst Noah Zatzkin maintains Malibu Boats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBUU#NASDAQ">MBUU</a>) with a Overweight and lowers the price target from $50 to $45.

MBUU

Keybanc Maintains Overweight on Malibu Boats, Lowers Price Target to $45

Cryptocurrency markets continued to slide lower on Wednesday.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$94,201.98</td>
<td>-2.3%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,279.33</td>
<td>-3.2%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$194.57</td>
<td>-4.9%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.32</td>
<td>+1.9%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.3362</td>
<td>-4.8%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00002113&nbsp;</td>
<td>-3.6%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 9% and daily active addresses falling by 0.08%. Transactions greater than $100,000 are up from 11,574 to 10,613 in a single day. Exchanges netflows are down by 401.2%.</li>
<li>Coinglass data reports 241,241 traders were liquidated in the past 24 hours for $643.68 million. Bitcoin derivates volume spiked 17.3% to $123.2 billion.</li>
<li>Quinten Francois noted whales are accumulating Bitcoin.</li>
</ul>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Whales are accumulating <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> &#x1f440; <a href="https://t.co/a9EcHWr3En">pic.twitter.com/a9EcHWr3En</a>
&mdash; Quinten &#x7C; 048.eth (@QuintenFrancois) <a href="https://twitter.com/QuintenFrancois/status/1877071778649866665?ref_src=twsrc%5Etfw">January 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42867736/us-bitcoin-miners-hoard-apex-crypto-to-shield-against-rising-expenses-mara-riot-replicate-microstrategys-playbook">US Bitcoin Miners Hoard Apex Crypto To Shield Against Rising Expenses — MARA, Riot Replicate MicroStrategy&#8217;s Playbook</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/25/01/42879720/microstrategy-launches-sovereign-european-cloud-with-stackit-details">MicroStrategy Launches Sovereign European Cloud With STACKIT: Details</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42870343/what-microstrategys-declining-net-asset-value-premium-really-means-for-bitcoin">What MicroStrategy&#8217;s (Declining) Net Asset Value Premium Really Means For Bitcoin</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42869884/jamie-dimon-questioned-bitcoins-21-million-cap-years-before-blackrock-heres-how-much-youd-have-if-you-invested-1000-into-btc-when-jpmorgan-ceo-shared-his-take">Jamie Dimon Questioned Bitcoin&#8217;s 21 Million Cap Years Before BlackRock — Here&#8217;s How Much You&#8217;d Have If You Invested $1,000 Into BTC When JPMorgan CEO Shared His Take</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42882375/92000-is-bitcoins-key-support-heres-what-top-analyst-says-will-happen-if-it-fails">$92,000 Is Bitcoin&#8217;s Key Support — Here&#8217;s What Top Analyst Says Will Happen If It Fails</a></li>
</ul>
Top Losers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Movement (CRYPTO: MOVE)</td>
<td>&nbsp;$0.8904</td>
<td>-12%</td>
</tr>
<tr>
<td>Worldcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WLD</a>)</td>
<td>&nbsp;$2.15&nbsp;&nbsp;</td>
<td>-10.4%</td>
</tr>
<tr>
<td>THORChain (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/rune/usd">RUNE</a>)</td>
<td>&nbsp;$3.98</td>
<td>-10.2%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin prices dropping below the $95,000 level, crypto trader Michael van de Poppe highlighted two key points: he initially expected a breakout and the start of a bull market at $100,000, but that hasn&#8217;t happened. 
Now, he <a href="https://x.com/CryptoMichNL/status/1877066490886893982">anticipates</a> a dip below the lows to take liquidity before reversing upward, targeting the $90,000-92,000 range.
Crypto trader Jelle sees Bitcoin touching 2025 levels tagged.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Finally some wicks, nice. 2025 lows tagged &#8211; let&#39;s see. <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://t.co/H3keXovhT6">pic.twitter.com/H3keXovhT6</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1877069060938109089?ref_src=twsrc%5Etfw">January 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto trader Kevin <a href="https://x.com/Kev_Capital_TA/status/1877067385473048950">notes</a> Bitcoin that Bitcoin reached $92,507 as forecasted, but there are liquidity blocks at $89,000-$90,000 that he hopes to avoid.
He observes bullish divergences forming on the daily timeframe for altcoins and prefers BTC to hold its current level.
CryptoCon points out that Bitcoin bull markets often begin with early-year volatility. 
In the past two cycles, initial January gains were followed by corrections, and this pattern is <a href="https://x.com/CryptoCon_/status/1877073697409839610">repeating</a> in the current cycle. 
Historical trends suggest that corrections are typically brief, ending within the month and followed by strong rallies into March.
Crypto trader Skew identifies $95,000 as the key level to watch for Bitcoin.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> One bullish thing so far is passive flow is leading the buying this forces takers to chase the market at a premium later, if sustained $95K key price here <a href="https://t.co/zz1fvHQhyx">pic.twitter.com/zz1fvHQhyx</a>
&mdash; Skew Δ (@52kskew) <a href="https://twitter.com/52kskew/status/1877057987740680369?ref_src=twsrc%5Etfw">January 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42881109/bitcoin-is-suffering-from-a-shift-in-macro-expectations-analyst-says-heres-what-that-means">Bitcoin Is Suffering From A Shift In Macro Expectations, Analyst Says: Here&#8217;s What That Means</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$RUNE

$SHIB

$SOL

$WLD

$XRP

Bitcoin, Ethereum, Dogecoin Lower 'Corrections Are Typically Short-Lived,' Trader Prefers Not Going To $89,000 To $90,000

Macro Economic Events

Economics

Gold and silver are trading higher amid geopolitical and economic uncertainty as investors assess president-elect Trump's tariff policies.

Keybanc analyst Scott Schoenhaus maintains LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) with a Overweight and lowers the price target from $10 to $7.

LFMD

Keybanc Maintains Overweight on LifeMD, Lowers Price Target to $7

Keybanc analyst Sangita Jain maintains KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) with a Overweight and lowers the price target from $78 to $70.

Keybanc Maintains Overweight on KBR, Lowers Price Target to $70

Keybanc analyst Scott Schoenhaus maintains GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) with a Overweight and lowers the price target from $7 to $6.

GDRX

Keybanc Maintains Overweight on GoodRx Holdings, Lowers Price Target to $6

<a href="https://www.cnbc.com/2025/01/08/medicare-can-now-cover-eli-lillys-zepbound-for-sleep-apnea-cms-says.html">https://www.cnbc.com/2025/01/08/medicare-can-now-cover-eli-lillys-zepbound-for-sleep-apnea-cms-says.html</a>
<ul>
<li>Medicare drug plans can now cover Eli Lilly's blockbuster obesity drug Zepbound for obstructive sleep apnea, the Centers for Medicare &amp; Medicaid Services confirmed to CNBC.</li>
<li>That opens the door for broader coverage of and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss specifically.</li>
<li>Medicare Part D plans can cover obesity drugs if they are used for an additional medically accepted purpose approved by the Food and Drug Administration.</li>
</ul>
Medicare drug plans can now cover <a href="https://www.cnbc.com/quotes/LLY/">Eli Lilly</a>'s blockbuster obesity drug <a href="https://zepbound.lilly.com/">Zepbound</a> for <a href="https://www.cnbc.com/2024/12/20/fda-approves-eli-lillys-weight-loss-drug-zepbound-for-sleep-apnea.html">obstructive sleep apnea</a>, CNBC confirmed on Wednesday.&nbsp;
That opens the door for broader access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss. Demand for the injection has soared over the last year despite its roughly <a href="https://pricinginfo.lilly.com/zepbound">$1,000 price tag</a> before insurance.
&nbsp;
In a statement to CNBC, a spokesperson for the Centers for Medicare &amp; Medicaid Services said "current Medicare Part D and Medicaid coverage rules apply" to Zepbound following its <a href="https://investor.lilly.com/news-releases/news-release-details/fda-approves-zepboundr-tirzepatide-first-and-only-prescription">landmark approval</a> last month for the most common sleep-related breathing disorder.
Medicare Part D plans can only cover obesity drugs if they are used for an <a href="https://www.cnbc.com/2024/03/21/medicare-can-cover-weight-loss-drugs-if-used-for-added-health-benefit.html">additional medically accepted purpose</a> approved by the Food and Drug Administration, the CMS spokesperson said, referring to the agency's <a href="https://aspe.hhs.gov/sites/default/files/documents/127bd5b3347b34be31ac5c6b5ed30e6a/medicare-coverage-anti-obesity-meds.pdf">guidance</a>. The spokesperson added that Part D plans may consider using prior authorization – a process where a provider must first get approval from an insurer – for those drugs to ensure they are being used for that specific purpose.&nbsp;
The FDA on Dec. 20 cleared Zepbound for patients with obesity and moderate-to-severe forms of obstructive sleep apnea, or OSA, which refers to breathing interrupted during sleep due to narrowed or blocked airways. That made Zepbound the first drug treatment cleared for the estimated 20 million people with those forms of the disease, according to Eli Lilly.
Medicare Part D plans are similarly allowed to cover <a href="https://www.cnbc.com/quotes/NVO/">Novo Nordisk</a>'s weight loss drug Wegovy for its <a href="https://www.prnewswire.com/news-releases/wegovy-receives-fda-approval-for-cardiovascular-risk-reduction-in-adults-with-known-heart-disease-and-overweight-or-obesity-302084454.html">other approved use</a> of lowering cardiovascular risks.&nbsp;The diabetes counterparts of Wegovy and Zepbound – Ozempic and Mounjaro, respectively – are covered by Medicare and most insurance plans.&nbsp;
Both Novo Nordisk and Eli Lilly are studying their weight loss medicines as treatments for fatty liver disease, chronic kidney disease, sleep apnea and more. To be covered, those drugs would need to return late-stage trial results and then be submitted for FDA approval for those uses.
&nbsp;
Meanwhile, state Medicaid coverage for Zepbound and other obesity medications depends on what condition they are prescribed for and whether their manufacturer has signed a certain <a href="https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html#:~:text=The%20Medicaid%20Drug%20Rebate%20Program,drugs%20dispensed%20to%20Medicaid%20patients.">Medicaid drug rebate agreement</a>, according to the spokesperson.&nbsp;
Under that agreement with the secretary of Health and Human Services, manufacturers agree to provide rebates to states in exchange for Medicaid coverage of their drugs. States share the rebates with the federal government.&nbsp;
A state Medicaid program must cover Zepbound if it is prescribed for OSA and Eli Lilly has signed the Medicaid drug rebate agreement, the spokesperson said.&nbsp;
But if Zepbound is prescribed for weight loss, state Medicaid programs are not required to cover it.&nbsp;
The Biden administration in November <a href="https://www.nbcnews.com/health/health-news/biden-proposes-requiring-medicare-medicaid-cover-weight-loss-drugs-rcna181756">proposed</a> a rule that would allow Medicare and Medicaid to cover weight loss drugs for patients with obesity. The rule would give millions of people access to weekly injectables, but it would cost taxpayers as much as $35 billion over the next decade.
It is unclear if President-elect Donald Trump's administration will pursue the rule.

Biotech

General

'Medicare Can Now Cover Eli Lilly's Zepbound For Sleep Apnea, CMS Says' - CNBC

Keybanc analyst Sangita Jain maintains Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) with a Overweight and raises the price target from $59 to $60.

Comments

Tofla Megaline

Tofla Megaline (TFLM) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga